Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Trial Details

NCT ID

NCT06767514

Phase

PHASE3

Sponsor

Summit Therapeutics

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

• Ivonescimab Injection
• Pembrolizumab Injection

Locations (sample)

• Chandler, Arizona, United States|33.30616,-111.84125
• Phoenix, Arizona, United States|33.44838,-112.07404
• Hot Springs, Arkansas, United States|34.5037,-93.05518
• Cerritos, California, United States|33.85835,-118.06479
• Glendale, California, United States|34.14251,-118.25508

Key Eligibility Criteria

• Age ≥ 18 years old at the time of enrollment
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1
• Expected life expectancy ≥ 3 months
• Metastatic (Stage IV) NSCLC

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.